Cancer patients with high SOX2-OT expression are more likely to have an advanced clinical stage, earlier lymphatic metastasis, earlier distant metastasis, a larger tumor size, and more extreme tumor invasion than those with low SOX2-OT expression [45]. This evidence concerns the gene SOX2 and cancer.